Curaleaf Holdings (CURLF) Share-based Compensation (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Share-based Compensation of -$20.4 million for Q4 2024, down 449.26% year-on-year from $5.8 million in Q1 2024, and down 438.52% on a QoQ basis from $6.0 million in Q3 2024.
Curaleaf Holdings (CURLF) Share-based Compensation (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Share-based Compensation for 6 consecutive years, with -$20.4 million the latest figure, recorded in Q4 2024.
- Quarterly Share-based Compensation fell 449.26% year-over-year to -$20.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$2.3 million (down 138.81% YoY) and the FY2025 annual result came in at $35.7 million, changed N/A from the prior year.
- Share-based Compensation retreated to -$20.4 million in Q4 2024 per CURLF's latest filing, from $6.0 million in the prior quarter.
- Over the last five years, Share-based Compensation for CURLF reached as high as $18.4 million in Q2 2021 and fell as low as -$20.4 million in Q4 2024.
- A 5-year average of $4.5 million and a median of $5.9 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation surged 189.25% — and 2022, when it slumped 633.27%.
- Year by year, Share-based Compensation stood at $13.1 million in 2020, then slumped by 76.88% to $3.0 million in 2021, then sank by 633.27% to -$16.1 million in 2022, then jumped by 136.17% to $5.8 million in 2023, then tumbled by 449.26% to -$20.4 million in 2024.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$20.4 million, $6.0 million, and $5.8 million for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -20.37 Mn |
| Dec 31, 2024 | -20.37 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Dec 31, 2022 | -16.13 Mn |
| Dec 31, 2022 | -16.13 Mn |
| Sep 30, 2022 | 9.99 Mn |
| Sep 30, 2022 | 9.99 Mn |
| Jun 30, 2022 | 6.04 Mn |
| Jun 30, 2022 | 6.04 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Dec 31, 2021 | 3.02 Mn |
| Dec 31, 2021 | 3.02 Mn |
| Sep 30, 2021 | 13.18 Mn |
| Sep 30, 2021 | 13.18 Mn |